Using CAR T cells to target a specific cancer marker in ovarian cancer patients
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer
This study is testing a new treatment for women with recurrent ovarian cancer that uses special immune cells to help the body fight the cancer more effectively, especially by delivering these cells directly where the cancer is likely to spread.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10914190 on NIH RePORTER |
What this research studies
This research focuses on developing a new immunotherapy approach for patients with recurrent epithelial ovarian cancer (EOC) by utilizing chimeric antigen receptor (CAR) T cell therapy. The therapy aims to retrain the immune system to recognize and attack cancer cells that express the TAG72 marker, which is prevalent in EOC. The study will explore the effectiveness of delivering these CAR T cells directly into the abdominal cavity, where the cancer often spreads, to enhance their anti-tumor activity. By addressing the challenges of tumor infiltration and persistence of T cells in the harsh tumor environment, this research seeks to improve treatment outcomes for patients with limited options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with recurrent epithelial ovarian cancer who have limited treatment options.
Not a fit: Patients with early-stage ovarian cancer or those whose cancer does not express the TAG72 marker may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with recurrent epithelial ovarian cancer.
How similar studies have performed: Other research has shown promising results with CAR T cell therapies in various cancers, indicating potential success for this novel approach in ovarian cancer.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Rodriguez-Rodriguez, Lorna — Beckman Research Institute/city of Hope
- Study coordinator: Rodriguez-Rodriguez, Lorna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.